The treatment of hepatitis C virus (HCV) infection has been revolutionised by the advent of oral, well-tolerated, direct acting antiviral therapies (DAA), with high cure rates. However, in some scenarios, HCV resistance to antiviral therapies may have an impact on treatment success. Public Health England's HCV Resistance Group was established to support clinicians treating people with HCV, where the issue of resistance may be a factor in clinical decision-making, and this review includes the Group's current recommendations on the use of HCV resistance testing. The authors describe the principles behind and approach to HCV resistance testing and consider evidence from in vitro studies, clinical trials and real world cohorts on the impact of HCV resistance on treatment outcomes for particular DAA regimens. Five scenarios are identified in the UK and similar settings, where, in the Group's opinion, resistance testing should be performed.

中文翻译：

---

慢性丙型肝炎病毒感染管理中耐药性检测的共识建议：英国公共卫生 HCV 耐药性小组。

随着口服、耐受性良好、直接作用的抗病毒疗法 (DAA) 的出现，丙型肝炎病毒 (HCV) 感染的治疗发生了革命性的变化，并且治愈率很高。然而，在某些情况下，HCV 对抗病毒治疗的耐药性可能会对治疗成功产生影响。英国公共卫生部的 HCV 耐药性小组成立的目的是支持临床医生治疗 HCV 患者，其中耐药性问题可能是临床决策中的一个因素，本次审查包括该小组目前关于使用 HCV 耐药性检测的建议。作者描述了 HCV 耐药性测试背后的原理和方法，并考虑了体外研究、临床试验和真实世界队列中关于 HCV 耐药性对特定 DAA 方案治疗结果的影响的证据。